BR0111732A - Prodrogas de 2-deóxi-beta-l-nucleosìdeos - Google Patents

Prodrogas de 2-deóxi-beta-l-nucleosìdeos

Info

Publication number
BR0111732A
BR0111732A BR0111732-7A BR0111732A BR0111732A BR 0111732 A BR0111732 A BR 0111732A BR 0111732 A BR0111732 A BR 0111732A BR 0111732 A BR0111732 A BR 0111732A
Authority
BR
Brazil
Prior art keywords
deoxy
nucleoside
hepatitis
compositions
nucleoside prodrugs
Prior art date
Application number
BR0111732-7A
Other languages
English (en)
Inventor
Martin L Bryant
Gilles Gosselin
Jean-Louis Imbach
Original Assignee
Idenix Cayman Ltd
Univ Montpellier Ii
Ct Nat Da La Rech Scient Cnrs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd, Univ Montpellier Ii, Ct Nat Da La Rech Scient Cnrs filed Critical Idenix Cayman Ltd
Publication of BR0111732A publication Critical patent/BR0111732A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"3'-PRODROGAS DE 2-DEóXI-<225>-L-NUCLEOSìDEOS". A presente invenção se refere a compostos, composições e métodos para o tratamento de um hospedeiro infectado com o vírus da hepatite B. Especificamente, compostos e composições de 3'-ésteres de 2'-deóxi-<225>-L-nucleosídeos são descritos, os quais podem ser administrados tanto sozinhos quanto em combinação com outros agentes anti vírus da hepatite B. Compostos e composições de 3',5'-ésteres de 2'-deóxi-<225>-L-nucleosídeos são descritos, os quais podem ser administrados tanto sozinhos quanto em combinação com outros agentes anti vírus da hepatite B, que são também descritos.
BR0111732-7A 2000-06-15 2001-06-15 Prodrogas de 2-deóxi-beta-l-nucleosìdeos BR0111732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21210000P 2000-06-15 2000-06-15
PCT/US2001/019147 WO2001096353A2 (en) 2000-06-15 2001-06-15 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES

Publications (1)

Publication Number Publication Date
BR0111732A true BR0111732A (pt) 2003-06-24

Family

ID=22789563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111732-7A BR0111732A (pt) 2000-06-15 2001-06-15 Prodrogas de 2-deóxi-beta-l-nucleosìdeos

Country Status (27)

Country Link
EP (1) EP1296995B1 (pt)
JP (1) JP4639032B2 (pt)
KR (2) KR20030032967A (pt)
CN (3) CN1295242C (pt)
AP (1) AP1771A (pt)
AR (1) AR035711A1 (pt)
AT (1) ATE411332T1 (pt)
AU (2) AU6692701A (pt)
BR (1) BR0111732A (pt)
CA (1) CA2413163C (pt)
CZ (1) CZ2003122A3 (pt)
DE (1) DE60136181D1 (pt)
EA (1) EA005774B1 (pt)
ES (1) ES2317912T3 (pt)
IL (3) IL153379A0 (pt)
MA (1) MA27126A1 (pt)
MX (1) MXPA02012443A (pt)
MY (1) MY141594A (pt)
NO (1) NO20026001L (pt)
NZ (2) NZ535246A (pt)
OA (1) OA12384A (pt)
PE (1) PE20020216A1 (pt)
PL (1) PL360404A1 (pt)
UY (1) UY26779A1 (pt)
WO (1) WO2001096353A2 (pt)
YU (1) YU94802A (pt)
ZA (2) ZA200300168B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404639A1 (en) 2000-04-13 2001-10-25 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
RS114104A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2498731C (en) 2002-09-13 2012-10-30 Idenix (Cayman) Limited .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
SI1576138T1 (sl) 2002-11-15 2017-07-31 Idenix Pharmaceuticals Llc 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
WO2004084453A2 (en) 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
US7595390B2 (en) 2003-04-28 2009-09-29 Novartis Ag Industrially scalable nucleoside synthesis
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
KR20060035652A (ko) 2003-06-30 2006-04-26 이데닉스 (케이만) 리미티드 β-Ｌ-2-데옥시 뉴클레오시드의 합성
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP2008546708A (ja) 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
NZ594812A (en) 2008-06-11 2012-12-21 Lasergen Inc Nucleotides and nucleosides and methods for their use in dna sequencing
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
UA122959C2 (uk) 2010-03-31 2021-01-27 Гайлід Фармассет Елелсі Нуклеозидфосфорамідати
AR094621A1 (es) 2010-04-01 2015-08-19 Idenix Pharmaceuticals Inc Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CN103906759A (zh) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
KR102048274B1 (ko) 2011-09-13 2019-11-25 애질런트 테크놀로지스, 인크. 핵산 시퀀싱을 위하여 5-메톡시, 3'-oh 차단안된, 신속하게 광절단가능한 종료 뉴클레오티드 및 핵산 시퀀싱 방법
KR101991298B1 (ko) 2011-09-16 2019-06-21 길리애드 파마셋 엘엘씨 Hcv 치료 방법
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
EP3650013A1 (en) 2013-01-31 2020-05-13 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
BR112020020804A2 (pt) 2018-04-12 2021-01-12 Modis Therapeutics Inc. Pró-fármacos de desoxinucleosídeos para tratamento de doenças causadas por agrupamentos de nucleotídeos não balanceados

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
SE9603178L (sv) * 1996-08-30 1997-09-22 Scania Cv Ab Anordning vid ett fordon för monterbar anfästning av en förarplatsmodul
AU5475799A (en) * 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis

Also Published As

Publication number Publication date
CN1452627A (zh) 2003-10-29
NO20026001D0 (no) 2002-12-13
CN1295242C (zh) 2007-01-17
DE60136181D1 (de) 2008-11-27
ZA200300168B (en) 2004-07-07
JP2004533403A (ja) 2004-11-04
ZA200404306B (en) 2005-06-15
IL153379A (en) 2007-02-11
KR20070048277A (ko) 2007-05-08
NO20026001L (no) 2003-02-12
ES2317912T3 (es) 2009-05-01
EP1296995A2 (en) 2003-04-02
AP1771A (en) 2007-08-23
OA12384A (en) 2006-04-17
AU2001266927B2 (en) 2006-12-14
NZ535246A (en) 2006-06-30
CN101012259A (zh) 2007-08-08
JP4639032B2 (ja) 2011-02-23
IL178864A0 (en) 2007-03-08
UY26779A1 (es) 2001-12-28
PL360404A1 (en) 2004-09-06
ATE411332T1 (de) 2008-10-15
YU94802A (sh) 2006-03-03
MA27126A1 (fr) 2005-01-03
EA200300023A1 (ru) 2003-08-28
CZ2003122A3 (cs) 2003-06-18
NZ523632A (en) 2005-03-24
CN1900104A (zh) 2007-01-24
AU6692701A (en) 2001-12-24
WO2001096353A3 (en) 2002-04-18
AP2003002713A0 (en) 2003-03-31
EA005774B1 (ru) 2005-06-30
CA2413163C (en) 2008-11-18
PE20020216A1 (es) 2002-04-16
WO2001096353A2 (en) 2001-12-20
MY141594A (en) 2010-05-14
IL153379A0 (en) 2003-07-06
KR20030032967A (ko) 2003-04-26
AR035711A1 (es) 2004-07-07
EP1296995B1 (en) 2008-10-15
MXPA02012443A (es) 2004-09-10
CA2413163A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2&#39;-ДЕЗОКСИНУКЛЕОЗИДОВ
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
BRPI0511834A (pt) métodos por tratar hepatite c
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31&#39; dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
BRPI0414045A (pt) administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
BR0206266A (pt) Heterocìclicos de difenila substituìda útil para tratar infecção por hcv
BRPI0515596A (pt) composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero
BR9712544A (pt) Inibidores de proteases de serina, particularmente protease ns3 do vìrus hapatite c
BRPI0716483B8 (pt) compostos inibidores do vírus da hepatite c e composição farmacêutica que os compreende
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
PT1404347E (pt) Nucleosidos 4&#39;-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
BRPI0514176A (pt) inibidores de replicação de hcv
BR0311132A (pt) Inibidores do vìrus da hepatite c
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
BR0313755A (pt) Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
ATE555794T1 (de) Heilmittel gegen hepatitis
PE61699A1 (es) Composicion farmaceutica de lamivudina
WO2009008924A3 (en) Methods of preventing and treating viral infections by inhibiting the deisgylation activity of otu domain-containing viral proteins

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.